

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Hansoh Pharmaceutical Group Company Limited

翰森製藥集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3692)

VOLUNTARY ANNOUNCEMENT LICENSE AGREEMENT WITH HENGRUI

The board (the “**Board**”) of directors (the “**Directors**”) of Hansoh Pharmaceutical Group Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that, on December 26, 2025, the Company entered into a license agreement (the “**License Agreement**”) with Jiangsu Hengrui Pharmaceuticals Co., Ltd. (the “**Licensor**”).

Pursuant to the License Agreement, the Company obtained an exclusive license from the Licensor to develop, manufacture and commercialize SHR6508 (the “**Product**”) in China (excludes Hong Kong, Macau and Taiwan), with the right of sublicense in accordance with the terms of the License Agreement. The Company shall pay the Licensor an upfront payment of RMB30 million, potential regulatory and commercialization milestone payments of up to RMB190 million and tiered single-digit royalties on potential future product net sales.

The Product is an allosteric modulator of the calcium-sensing receptor (CaSR) that increases the receptor’s sensitivity to extracellular calcium, thereby reducing parathyroid hormone (PTH) secretion. The Product is currently in Phase III clinical trial and being developed for the treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease who require hemodialysis.

The Licensor is a leading innovative global pharmaceutical company rooted in China, the A shares of which have been listed on the Shanghai Stock Exchange (stock code: 600276) and the H shares of which are listed on Main Board of The Stock Exchange of Hong Kong Limited (stock code: 1276). The Licensor is principally engaged in the R&D, manufacture and sale of pharmaceutical products.

The License Agreement is expected to be mutually beneficial to the parties. The Product is complementary to the Group’s existing nephrology portfolio, including dialysis-related applications. The Group intends to leverage its established commercialization infrastructure and market access capabilities in the nephrology and dialysis fields to enhance execution efficiency and overall portfolio performance. The Board considers that the License Agreement is in the best interests of the Company and its shareholders as a whole.

LISTING RULES IMPLICATION

For the purpose of Chapter 14 of the Listing Rules, as all the applicable percentage ratios in respect of the payments payable under the License Agreement are below 5%, the transactions contemplated under the License Agreement do not constitute any notifiable transaction under Chapter 14 of the Listing Rules. Furthermore, the transactions contemplated under the License Agreement do not constitute any connected transactions of the Company under Chapter 14A of the Listing Rules.

The shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By Order of the Board
Hansoh Pharmaceutical Group Company Limited
Zhong Huijuan
Chairlady

Hong Kong, December 26, 2025

As at the date of this announcement, the Board comprises Ms. Zhong Huijuan as chairlady and executive Director, Ms. Sun Yuan and Dr. Lyu Aifeng as executive Directors, and Mr. Lin Guoqiang, Mr. Chan Charles Sheung Wai and Ms. Yang Dongtao as independent non-executive Directors.